LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -18.2% | 8 | 0.0% | 0.00% | – |
| Q2 2023 | $11 | -8.3% | 8 | 0.0% | 0.00% | – |
| Q1 2023 | $12 | +33.3% | 8 | 0.0% | 0.00% | – |
| Q4 2022 | $9 | – | 8 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 8 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
| Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
| Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
| Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
| DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
| Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
| Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
| XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
| Ergoteles LLC | 490,895 | $555,000 | 0.02% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |